WHO ICTRP trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study…
NL-OMON53854 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON53854 |
|---|---|
| Public title | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington*s Disease |
| Scientific title | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington*s Disease - Phase 1b/2a Study of WVE-003 in Patients with Huntington's Disease |
| Primary sponsor | Wave Life Sciences UK Limited |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom |
| Conditions | Huntington's Disease;10027664;Huntington's Disease |
| Interventions | The currently planned starting dose level in Period 1 is 30 mg. The dose levels in subsequent Period 1 cohorts and Period 2 will be determined based on the findings in Period 1 and pending repeat-dose toxicity data from the GLP studies. The… |
| Registration date | Jun 16, 2023 |
| Target size | 4 |
| Secondary IDs | 2020-004556-15;NCT05032196;NL79700.000.22 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: